Multiple sclerosis:: Pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-β

被引:77
作者
Özenci, V [1 ]
Kouwenhoven, M [1 ]
Teleshova, N [1 ]
Pashenkov, M [1 ]
Fredrikson, S [1 ]
Link, H [1 ]
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Unit Neuroimmunol, Div Neurol, S-14186 Huddinge, Sweden
关键词
multiple sclerosis; cytokines; ELISPOT; interferon-beta; metalloproteinases;
D O I
10.1016/S0165-5728(00)00281-2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Interferon-beta (IFN-beta) has a beneficial influence on the course of multiple sclerosis (MS) and has become standard treatment of this disease, though its mechanisms of action are incompletely understood. This study examines the effect of IFN-beta treatment on the cytokines IL-6, TNF-alpha, IFN-gamma and IL-10; the metalloproteinases MMP-3, -7 and -9 and the tissue inhibitor of metalloproteinase-1 (TIMP-1). IFN-beta treatment resulted in decreased numbers of mononuclear cells (MNC) secreting IL-6 and TNF-alpha and expressing mRNA of MMP-3 and MMP-9 compared to pretreatment levels. On the contrary, numbers of IL-10 secreting MNC and TIMP-1 mRNA expressing were augmented during IFN-beta therapy. Whether the down-regulatory effects on pro-inflammatory and upregulatory effects on anti inflammatory molecules are a direct result of IFN-beta on the immune system or secondary to clinical stabilization of MS pathology induced by IFN-beta remains to be evaluated. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:236 / 243
页数:8
相关论文
共 27 条
[11]   Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis [J].
Kappos, L ;
Polman, C ;
Pozzilli, C ;
Thompson, A ;
Dahlke, F ;
Knight, R ;
Hern, J ;
Coleman, R ;
Gerrie, L ;
Cooper, G ;
Moore, J ;
Boringa, J ;
van Oosten, B ;
Ronner, H ;
Schrijver, H ;
Truyen, L ;
Montalbán, J ;
Río, J ;
Tintoré, M ;
Jacas, C ;
Marzo, E ;
Lechner-Scott, J ;
Huber, S ;
Lienert, C ;
Brunnschweiler, H ;
Hawkins, S ;
Droogan, A ;
McDonnell, G ;
Duddy, M ;
McKinstry, S ;
Altenkirch, H ;
Baum, K ;
Einhäupl, K ;
Marx, P ;
Poewe, W ;
Walter, G ;
Akman, H ;
Brockmeier, B ;
Scherer, P ;
Zschenderlein, R ;
Schmierer, K ;
Gelderblom, H ;
Hartmann, A ;
Stapf, C ;
Lüschow, A ;
Mackert, B ;
Schumacher, H ;
Masuhr, F ;
Hempel, T ;
Zimmermann, R .
LANCET, 1998, 352 (9139) :1491-1497
[12]  
KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
[13]   Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis - A longitudinal clinical and MRI study [J].
Lee, MA ;
Palace, J ;
Stabler, G ;
Ford, J ;
Gearing, A ;
Miller, K .
BRAIN, 1999, 122 :191-197
[14]   Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis [J].
Leppert, D ;
Waubant, E ;
Burk, MR ;
Oksenberg, JR ;
Hauser, SL .
ANNALS OF NEUROLOGY, 1996, 40 (06) :846-852
[15]   ORGAN-SPECIFIC AUTOANTIGENS INDUCE INTERFERON-GAMMA AND INTERLEUKIN-4 MESSENGER-RNA EXPRESSION IN MONONUCLEAR-CELLS IN MULTIPLE-SCLEROSIS AND MYASTHENIA-GRAVIS [J].
LINK, J ;
SODERSTROM, M ;
LJUNGDAHL, A ;
HOJEBERG, B ;
OLSSON, T ;
XU, Z ;
FREDRIKSON, S ;
WANG, ZY ;
LINK, H .
NEUROLOGY, 1994, 44 (04) :728-734
[16]   CNTF PROTECTION OF OLIGODENDROCYTES AGAINST NATURAL AND TUMOR NECROSIS FACTOR-INDUCED DEATH [J].
LOUIS, JC ;
MAGAL, E ;
TAKAYAMA, S ;
VARON, S .
SCIENCE, 1993, 259 (5095) :689-692
[17]  
Özenci V, 1999, SCAND J IMMUNOL, V49, P554
[18]   Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-α)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-β) treatment [J].
Özenci, V ;
Kouwenhoven, M ;
Huang, YM ;
Kivisäkk, P ;
Link, H .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2000, 120 (01) :147-153
[19]   Metalloproteinases and their tissue inhibitors in multiple sclerosis [J].
Özenci, V ;
Rinaldi, L ;
Teleshova, N ;
Matusevicius, D ;
Kivisäkk, P ;
Kouwenhoven, M ;
Link, H .
JOURNAL OF AUTOIMMUNITY, 1999, 12 (04) :297-303
[20]   NEW DIAGNOSTIC-CRITERIA FOR MULTIPLE-SCLEROSIS - GUIDELINES FOR RESEARCH PROTOCOLS [J].
POSER, CM ;
PATY, DW ;
SCHEINBERG, L ;
MCDONALD, WI ;
DAVIS, FA ;
EBERS, GC ;
JOHNSON, KP ;
SIBLEY, WA ;
SILBERBERG, DH ;
TOURTELLOTTE, WW .
ANNALS OF NEUROLOGY, 1983, 13 (03) :227-231